Korro Bio, Inc. Increase (Decrease) in Other Operating Assets
Korro Bio, Inc. (KRRO) reported Increase (Decrease) in Other Operating Assets of -$28.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingAssets · last filed 2026-08-06
- Korro Bio, Inc. increase (decrease) in other operating assets for the quarter ending 2026-06-30 was $104.00K, a 215.15% increase year-over-year.
- Korro Bio, Inc. increase (decrease) in other operating assets for the quarter ending 2026-03-31 was -$132.00K, a 132.51% decline year-over-year.
- Korro Bio, Inc. increase (decrease) in other operating assets for the quarter ending 2025-12-31 was -$573.00K.
- Korro Bio, Inc. increase (decrease) in other operating assets for the quarter ending 2025-09-30 was -$136.00K.
- Korro Bio, Inc. increase (decrease) in other operating assets for fiscal 2025 was -$270.00K.
- Korro Bio, Inc. increase (decrease) in other operating assets for fiscal 2024 was -$340.00K, a 117.11% decline from fiscal 2023.
- Korro Bio, Inc. increase (decrease) in other operating assets for fiscal 2023 was $1.99M, a 1515.45% increase from fiscal 2022.
- Korro Bio, Inc. increase (decrease) in other operating assets for fiscal 2022 was $123.00K.
| Period end | Increase (Decrease) in Other Operating Assets 3 month | Increase (Decrease) in Other Operating Assets 6 month | Increase (Decrease) in Other Operating Assets 9 month | Increase (Decrease) in Other Operating Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$28.00K 10-Q · filed 2026-08-06 | -$601.00K derived: sum of 3 quarters · filed 2026-08-06 | -$737.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$132.00K 10-Q · filed 2026-05-07 | -$705.00K derived: sum of 2 quarters · filed 2026-05-07 | -$841.00K derived: sum of 3 quarters · filed 2026-05-07 | -$808.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$573.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$709.00K derived: sum of 2 quarters · filed 2026-03-12 | -$676.00K derived: sum of 3 quarters · filed 2026-08-06 | -$270.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | -$136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$103.00K derived: sum of 2 quarters · filed 2026-08-06 | $303.00K 10-Q · filed 2025-11-12 | $193.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $33.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $439.00K 10-Q · filed 2026-08-06 | $329.00K derived: sum of 3 quarters · filed 2026-08-06 | $271.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $406.00K 10-Q · filed 2026-05-07 | $296.00K derived: sum of 2 quarters · filed 2026-05-07 | $238.00K derived: sum of 3 quarters · filed 2026-05-07 | $152.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$168.00K derived: sum of 2 quarters · filed 2026-03-12 | -$254.00K derived: sum of 3 quarters · filed 2026-03-12 | -$340.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | -$58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$144.00K derived: sum of 2 quarters · filed 2025-11-12 | -$230.00K 10-Q · filed 2025-11-12 | $1.89M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$86.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$172.00K 10-Q · filed 2025-08-12 | $1.95M derived: sum of 3 quarters · filed 2025-08-12 | $1.83M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$86.00K 10-Q · filed 2025-05-07 | $2.04M derived: sum of 2 quarters · filed 2025-05-07 | $1.91M derived: sum of 3 quarters · filed 2025-05-07 | $1.90M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $2.00M derived: sum of 2 quarters · filed 2025-03-18 | $1.99M derived: sum of 3 quarters · filed 2025-03-18 | $1.99M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$124.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$139.00K derived: sum of 2 quarters · filed 2024-11-12 | -$137.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$13.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $2.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $123.00K 10-K · filed 2024-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |